(Q37852720)

24 August 2017

1 reference

title

Tolvaptan for the treatment of heart failure: a review of the literature (English)

1 reference

24 August 2017

0 references

3

Mihai Gheorghiade

1 reference

24 August 2017

Andrew Ambrosy

1

1 reference

24 August 2017

Steven R Goldsmith

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

961-976

1 reference

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

The current and future management of acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Vasopressin: a new target for the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Congestion in acute heart failure syndromes: an essential target of evaluation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Pathophysiologic targets in the early phase of acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Left ventricular filling and stress response pattern in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Alpha-adrenergic mechanisms in myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Pharmacology of new agents for acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind st

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Acute heart failure syndromes: current state and framework for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Oral tolvaptan is safe and effective in chronic hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Vasopressin antagonism in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.567267

10.1517/14656566.2011.567267

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference